Akebia Therapeutics Inc. (NASDAQ:AKBA) shares were down 2.2% on Friday . The company traded as low as $7.90 and last traded at $7.91, with a volume of 80,532 shares changing hands. The stock had previously closed at $8.09.

A number of research analysts have weighed in on AKBA shares. Morgan Stanley reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research note on Sunday, May 8th. Brean Capital reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research note on Sunday, May 8th. Zacks Investment Research lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. HC Wainwright reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research note on Monday, May 16th. Finally, Credit Suisse Group AG reaffirmed a “hold” rating on shares of Akebia Therapeutics in a research note on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $15.75.

The stock’s 50 day moving average price is $8.46 and its 200-day moving average price is $8.46. The firm’s market cap is $148.41 million.

Akebia Therapeutics (NASDAQ:AKBA) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.38. Analysts predict that Akebia Therapeutics Inc. will post ($3.73) EPS for the current fiscal year.

A hedge fund recently raised its stake in Akebia Therapeutics stock. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 97,925 shares of the biopharmaceutical company’s stock after buying an additional 8,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.54% of Akebia Therapeutics worth $1,265,000 at the end of the most recent quarter.

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.